AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation

NASDAQ:AMRX • US03168L1052

Current stock price

13.05 USD
-0.07 (-0.53%)
At close:
13.23 USD
+0.18 (+1.38%)
After Hours:

This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. AMRX Profitability Analysis

1.1 Basic Checks

  • AMRX had positive earnings in the past year.
  • AMRX had a positive operating cash flow in the past year.
  • In multiple years AMRX reported negative net income over the last 5 years.
  • In the past 5 years AMRX always reported a positive cash flow from operatings.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of AMRX (1.96%) is better than 82.20% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.24%, AMRX belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
  • AMRX had an Average Return On Invested Capital over the past 3 years of 10.04%. This is below the industry average of 13.10%.
  • The 3 year average ROIC (10.04%) for AMRX is below the current ROIC(11.24%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROIC 11.24%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin of AMRX (2.39%) is better than 80.63% of its industry peers.
  • AMRX's Profit Margin has declined in the last couple of years.
  • AMRX has a Operating Margin of 13.18%. This is amongst the best in the industry. AMRX outperforms 85.34% of its industry peers.
  • In the last couple of years the Operating Margin of AMRX has grown nicely.
  • AMRX has a Gross Margin (36.88%) which is in line with its industry peers.
  • AMRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. AMRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
  • The number of shares outstanding for AMRX has been increased compared to 1 year ago.
  • Compared to 5 years ago, AMRX has more shares outstanding
  • AMRX has a better debt/assets ratio than last year.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • AMRX has an Altman-Z score of 1.98. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • AMRX has a Altman-Z score of 1.98. This is comparable to the rest of the industry: AMRX outperforms 59.16% of its industry peers.
  • AMRX has a debt to FCF ratio of 11.66. This is a negative value and a sign of low solvency as AMRX would need 11.66 years to pay back of all of its debts.
  • AMRX has a Debt to FCF ratio of 11.66. This is in the better half of the industry: AMRX outperforms 78.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Altman-Z 1.98
ROIC/WACC1.17
WACC9.58%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.17. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMRX (2.17) is comparable to the rest of the industry.
  • AMRX has a Quick Ratio of 1.48. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
  • AMRX has a Quick ratio of 1.48. This is in the lower half of the industry: AMRX underperforms 67.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.17
Quick Ratio 1.48
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMRX Growth Analysis

3.1 Past

  • AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.83%, which is quite impressive.
  • The Earnings Per Share has been growing slightly by 5.92% on average over the past years.
  • AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.05%.
  • Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 8.66% on average per year.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.77% on average over the next years.
  • Based on estimates for the next years, AMRX will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

8

4. AMRX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.54, the valuation of AMRX can be described as correct.
  • Based on the Price/Earnings ratio, AMRX is valued cheaper than 85.86% of the companies in the same industry.
  • AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.38.
  • With a Price/Forward Earnings ratio of 12.92, AMRX is valued correctly.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.77% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.20, AMRX is valued rather cheaply.
Industry RankSector Rank
PE 15.54
Fwd PE 12.92
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 87.43% of the companies in the same industry.
  • 85.34% of the companies in the same industry are more expensive than AMRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 18.45
EV/EBITDA 10.51
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of AMRX may justify a higher PE ratio.
  • AMRX's earnings are expected to grow with 18.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.77
PEG (5Y)2.62
EPS Next 2Y19.5%
EPS Next 3Y18.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRX Dividend Analysis

5.1 Amount

  • AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRX Fundamentals: All Metrics, Ratios and Statistics

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (4/15/2026, 8:00:00 PM)

After market: 13.23 +0.18 (+1.38%)

13.05

-0.07 (-0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-01
Inst Owners45.62%
Inst Owner Change0.05%
Ins Owners43.95%
Ins Owner Change8.28%
Market Cap4.16B
Revenue(TTM)3.02B
Net Income(TTM)72.06M
Analysts81.82
Price Target16.83 (28.97%)
Short Float %4.33%
Short Ratio3.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)11.53%
Max EPS beat(2)21.21%
EPS beat(4)4
Avg EPS beat(4)28.29%
Min EPS beat(4)11.53%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)21.12%
EPS beat(12)11
Avg EPS beat(12)30.53%
EPS beat(16)12
Avg EPS beat(16)21.16%
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-2.73%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.1%
Revenue beat(16)8
Avg Revenue beat(16)-0.09%
PT rev (1m)13.79%
PT rev (3m)17.86%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)-14.47%
EPS NY rev (1m)3.53%
EPS NY rev (3m)6.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.81%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-3.78%
Valuation
Industry RankSector Rank
PE 15.54
Fwd PE 12.92
P/S 1.38
P/FCF 18.45
P/OCF 12.24
P/B N/A
P/tB N/A
EV/EBITDA 10.51
EPS(TTM)0.84
EY6.44%
EPS(NY)1.01
Fwd EY7.74%
FCF(TTM)0.71
FCFY5.42%
OCF(TTM)1.07
OCFY8.17%
SpS9.46
BVpS-0.22
TBVpS-3.86
PEG (NY)0.77
PEG (5Y)2.62
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 1.96%
ROE N/A
ROCE 14.23%
ROIC 11.24%
ROICexc 12.5%
ROICexgc 23.19%
OM 13.18%
PM (TTM) 2.39%
GM 36.88%
FCFM 7.47%
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
ROICexc(3y)10.72%
ROICexc(5y)8.59%
ROICexgc(3y)22.54%
ROICexgc(5y)18.52%
ROCE(3y)13.13%
ROCE(5y)10.51%
ROICexgc growth 3Y26.84%
ROICexgc growth 5Y18.51%
ROICexc growth 3Y34.73%
ROICexc growth 5Y26.54%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.66
Debt/EBITDA 4.22
Cap/Depr 51.15%
Cap/Sales 3.79%
Interest Coverage 2.01
Cash Conversion 54.71%
Profit Quality 313.13%
Current Ratio 2.17
Quick Ratio 1.48
Altman-Z 1.98
F-Score7
WACC9.58%
ROIC/WACC1.17
Cap/Depr(3y)37.69%
Cap/Depr(5y)34.67%
Cap/Sales(3y)3.12%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%
EBIT growth 1Y14.22%
EBIT growth 3Y25.92%
EBIT growth 5Y22.25%
EBIT Next Year43.16%
EBIT Next 3Y20.98%
EBIT Next 5Y8.1%
FCF growth 1Y2.51%
FCF growth 3YN/A
FCF growth 5Y-6.32%
OCF growth 1Y15.21%
OCF growth 3Y73.5%
OCF growth 5Y-2.15%

AMNEAL PHARMACEUTICALS INC / AMRX Fundamental Analysis FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


Can you provide the profitability details for AMNEAL PHARMACEUTICALS INC?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for AMRX stock?

The Price/Earnings (PE) ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 15.54 and the Price/Book (PB) ratio is -58.8.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 20.21% in the next year.